SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?


To: Alys Hall who wrote (1159)1/27/1998 12:36:00 AM
From: Alys Hall  Respond to of 3702
 
For those of you too new to remember and for those of you who need reminding, I bring to your attention...posts of the past:
www3.techstocks.com
Message 2894714
www3.techstocks.com www3.techstocks.com
Message 2897137

And who was calling the pot black? Why good old Jim Baker...where are you now Jim...want to tell us how stupid we are for questioning the sheer genius of our management group? And Davis, through it all, you've been the cheerleader...Now what?



To: Alys Hall who wrote (1159)1/27/1998 2:54:00 AM
From: Maurice Winn  Respond to of 3702
 
"Or will we now be left with a debate, useless though it may be, on whether or not the stock gets delisted." I'm not sure, but I think with a market capitalisation of $28 million, Techniclone stays listed even though it might drop below $1. $1 is the limit for much lower capitalisations - not sure what, but I think more like a couple of million dollars. So there is a long way to go before you need contend with that. Maybe wrong, but that's my understanding. Even then, the assets of the company don't go away. You still own a going concern with maybe big profits to come. It is irrelevant to owners what new buyers are paying for shares - apart from dilution in which case you should be getting an opportunity before new shareholders to put more money in to maintain operations and your proportion of shareholding.

I realize you need to have $1.10 to buy another share - but that is bad luck if you don't have it and the way dilution works. Although it looks very interesting to me, I haven't yet bought shares, because I'm not confident that the company has $34 million value.

They bought back some rights to Oncolym as well as vasopermeation technology. Assuming they didn't pay too much, then that is a passable valuation of the company. Second hand furniture isn't too valuable. Suppose IDEC bought the assets, what do you suppose they'd pay? Surely not more than Lon Stone agreed to pay for the remaining Oncolym and vasopermeation rights.

How about listing [for the ignorant potential new shareholders like me] the technology to which they hold exlusive rights and the valuations. Or direct me to the source of this information. If it looks good, we'll buy in and that will help hold the price and protect you against further dilution.

I did see that Oncolym second year profits should = the market capitalisation [$30million]. Maybe. I'd have to work that out. At the moment it is an unproven bird in the bush having only completed preliminary trials for efficacy and safety on a few dozen people.

Maurice